Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses

Hepatocellular carcinoma (HCC) accounts for up to 90% of primary liver cancer occurrences worldwide. Lenvatinib, a multikinase inhibitor, was approved in radioiodine‐refractory differentiated thyroid cancer. In this phase 2 study (study 202), we aimed to identify the lenvatinib optimal dose for subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamai, Toshiyuki, Hayato, Seiichi, Hojo, Seiichiro, Suzuki, Takuya, Okusaka, Takuji, Ikeda, Kenji, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575539/
https://www.ncbi.nlm.nih.gov/pubmed/28561918
http://dx.doi.org/10.1002/jcph.917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575539/
https://www.ncbi.nlm.nih.gov/pubmed/28561918
http://dx.doi.org/10.1002/jcph.917

Ejemplares similares